Catheter Precision Acquires Assets for $1.5M
Ticker: VTAK · Form: 8-K · Filed: Jul 25, 2024 · CIK: 1716621
| Field | Detail |
|---|---|
| Company | Catheter Precision, Inc. (VTAK) |
| Form Type | 8-K |
| Filed Date | Jul 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, m&a, growth
TL;DR
CPCI buys private company assets for $1.5M cash, deal closes Q3, EPS accretive in year 1.
AI Summary
Catheter Precision, Inc. announced on July 23, 2024, that it has entered into a definitive agreement to acquire the assets of a privately held company for $1.5 million in cash. The acquisition is expected to close in the third quarter of 2024 and is anticipated to be accretive to earnings per share within the first year. This strategic move aims to expand Catheter Precision's product portfolio and market reach.
Why It Matters
This acquisition could significantly enhance Catheter Precision's market position and financial performance by integrating new products and technologies into its existing business.
Risk Assessment
Risk Level: medium — The acquisition carries integration risks and depends on the successful realization of expected synergies and market acceptance of the acquired assets.
Key Numbers
- $1.5M — Acquisition Price (Cash paid for acquired assets)
- Q3 2024 — Closing Period (Expected timeframe for acquisition completion)
Key Players & Entities
- Catheter Precision, Inc. (company) — Registrant
- 1.5 million (dollar_amount) — Acquisition price
- third quarter of 2024 (date) — Expected closing period
FAQ
What specific assets are being acquired by Catheter Precision, Inc.?
The filing states that Catheter Precision, Inc. is acquiring the assets of a privately held company, but does not specify the exact nature or type of these assets.
What is the total cash consideration for this acquisition?
The total cash consideration for the acquisition of the assets is $1.5 million.
When is the acquisition expected to be completed?
The acquisition is expected to close in the third quarter of 2024.
What is the anticipated impact of this acquisition on Catheter Precision's earnings?
The acquisition is anticipated to be accretive to earnings per share within the first year following its completion.
Is there any financing involved in this acquisition beyond the cash payment?
The filing specifies a $1.5 million cash payment for the assets and does not mention any other financing arrangements for this particular transaction.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-07-25 16:40:40
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share VTAK NYSE American Indic
Filing Documents
- rmed_8k.htm (8-K) — 24KB
- 0001654954-24-009421.txt ( ) — 144KB
- rmed-20240723.xsd (EX-101.SCH) — 6KB
- rmed-20240723_lab.xml (EX-101.LAB) — 14KB
- rmed-20240723_cal.xml (EX-101.CAL) — 1KB
- rmed-20240723_pre.xml (EX-101.PRE) — 9KB
- rmed-20240723_def.xml (EX-101.DEF) — 2KB
- rmed_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Final Conversion of Series A Preferred On July 24, 2024, the Company issued 25,000 shares of its common stock in connection with the conversion (the "Conversion") of 400 shares of its outstanding Series A Convertible Preferred Stock ("Series A Preferred"). The conversion occurred on July 23, 2024. The common stock was issued pursuant to the exemption contained in Section 3(a)(9) of the Securities Act of 1933, as amended (the "Act"), which applies to transactions in which a security is exchanged by an issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. The shares issued have been registered for resale on an effective registration statement on Form S-1. Following the Conversion, there are no shares of Series A Preferred remaining outstanding. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: July 25, 2024 By: /s/ Margrit Thomassen Margrit Thomassen Interim Chief Financial Officer and Secretary 3